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CD28 Superagonistic Activation of T Cells Induces a Tumor
Cell-Like Metabolic Program
Thilipan Thaventhiran,1 Wai Wong,1 Ahmad F. Alghanem,1,* Naif Alhumeed,1 Mohammad A. Aljasir,1,{
Simeon Ramsey,2 Swaminathan Sethu,1,{ Han Xian Aw Yeang,1,x Amy E. Chadwick,1 Michael Cross,1
Steven D. Webb,1,** Laiche Djouhri,3 Christina Ball,4 Richard Stebbings,4,{{ and Jean G. Sathish1,{{
CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and
exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse
effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In
this study, we show that human CD4+ TEMs stimulated with CD28SA adopt a metabolic program similar to
those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic con-
ditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to
test safety of immunostimulatory antibodies.
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Introduction
C D28 superagonists (CD28SAs) are monoclonal anti-bodies (mAbs) that engage CD28 costimulatory recep-
tors resulting in potent T cell activation independent of
concomitant T cell receptor (TCR) engagement.(1) TGN1412,
a CD28SA, triggered an excessive and adverse cytokine re-
lease (cytokine storm) when administered to volunteers in
a human Phase 1 clinical trial.(2) We and others have shown
that CD28SA induces exaggerated activation, polyclonal
expansion, and migration of CD4+ effector memory T cells
(TEMs).
(2–4) The basis for this hyperactive, dysregulated
phenotype is subject of much research and the lack of in-
hibitory inputs(4) has been suggested as one potential mech-
anism. T cells need to undergo metabolic reprogramming to
adapt to their changing metabolic needs as they progress from
resting T cells to fully differentiated effectors and memory
cells.(5,6)
T cells utilize glucose as the primary nutrient source for
energy generation and biomass production, although amino
acids, such as glutamine, are also utilized.(5) Before activa-
tion, naive T cells have low metabolic requirements and rely
on mitochondrial oxidative pathways for basal energy gen-
eration. Upon activation, T cells adopt a metabolic profile
typified by aerobic glycolysis and basal oxidative phos-
phorylation (OXPHOS).(5,7) Rapidly proliferating T cells
require lipids to support membrane biogenesis and depending
on the T cell subset, lipids may be acquired or synthesized
(lipogenesis).(8) T cells use distinct metabolic programs ac-
cording to their differentiation state and immunological role.
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Studies have shown that CD4+ T helper (Th)1, Th2, and Th17
cells are highly glycolytic, whereas CD4+ regulatory T cells
have high lipid oxidation rates.(9) The metabolic phenotype
of the TGN1412-target cell, CD4+ TEMs, is yet to be fully
characterized. Importantly, the metabolic program that sup-
ports the dramatic hyperactivation and proliferation induced
by CD28SA is currently unknown.
Tumor cells exhibit metabolic abnormalities such as ele-
vated aerobic glycolysis and de novo fatty acid biosynthesis
to generate the energy required to support rapid cell divi-
sion.(10) In this report, we demonstrate that superagonistic
activation programs CD4+ TEMs toward a tumor cell-like
metabolic profile that favors enhanced glycolysis and lipo-
genesis. We also define ATP-citrate lyase (ACL) and acetyl-
Coenzyme A (ACC) as key molecular indicators of the
CD28SA-induced lipogenic phenotype.
Materials and Methods
Reagents
All reagents were obtained from Sigma-Aldrich (United
Kingdom) unless otherwise stated.
Effector memory T cell isolation
Ethics approval for the use of human peripheral blood
mononuclear cells (PBMCs) from healthy donors was given
by the local Ethics Committee and all subjects provided in-
formed consent. PBMCs were isolated from heparinized
venous blood by density gradient separation (LymphoPrep,
O7811; Axis-Shield). The CD4+ TEMs isolation kit (130–
094–125; Miltenyi Biotec) was used to purify TEMs from
PBMCs according to the manufacturer’s instructions.
Stimulating antibodies
Humanized superagonistic anti-CD28 antibody, NIB1412,
a human IgG4 sharing the H chain V region and L chain
sequences of TGN1412, was generated at the National In-
stitute for Biological Standards and Control (NIBSC, United
Kingdom). Murine anti-human CD3 (clone: UCHT1, Cat No.
16–0038–85) antibody was purchased from eBioscience
(United Kingdom).
Proliferation assays
Plate-bound or solid-phase PBMC in vitro systems have
been previously shown to support robust T cell activation by
anti-CD3 and CD28SA,(4,11) and therefore this system was
chosen to study metabolic reprogramming of TEM cells.
Ninety-six-well round-bottom non tissue culture treated
plates were coated with stimulating antibodies at 37C for 2
hours. Plates were washed twice to remove unbound antibody
before addition of T cells. The T cells were cultured in
complete media (RPMI 1640 supplemented with 15% fetal
calf serum (Life Technologies, United Kingdom), 2 mM
l-glutamine, 50 U/mL penicillin, and 0.05 mg/mL strepto-
mycin) for 72 hours (at 37C) in either normoxic (20% O2) or
hypoxic (5% O2) conditions. The cells were pulsed with tri-
tiated thymidine ([3H]-TdR, 0.5 mCi/well), 18 hours before
the end of the indicated time point. Incorporation of [3H]-
TdR in T cells was determined using a b-scintillation counter
(MicroBetaTrilux; PerkinElmer Life Sciences, United
Kingdom). Data obtained are represented as mean counts per
minute.
Cell viability assay
Briefly, CD4+ TEMs were plated in base media with
l-glutamine – glucose at a density of 5 · 104 cells per well in
96-well plates precoated with anti-CD3 mAbs or NIB1412.
Following overnight incubation at 37C, each sample was
collected and assayed for cell viability using Trypan Blue
exclusion. Percentage viability was determined by the
Countess automated cell counter.
Flow cytometric analysis
CD4+ TEMs were activated with plate-bound anti-CD3 or
NIB1412 for 48 hours. For the quantification of mitochondria,
cells were stained with MitoTracker Deep Red FM (M22426;
Molecular Probes) at 20 nM during the last 30 minutes of
treatment. Cells were washed with phosphate-buffered saline
(PBS) and fixed with 4% paraformaldehyde and stained with
HCS LipidTOX Green Neutral Lipid Stain (H34475; In-
vitrogen) at 1:500. To quantify mitochondrial superoxide pro-
duction, cells were incubated with MitoSOX Red (Cat No.
M36008; Invitrogen) at 37C for 10 minutes, washed and fixed
in 2% paraformaldehyde. MitoSOX Red was excited at 488 nm
and fluorescence emission at 575 nm was measured.
For the determination of glucose uptake and cell surface
expression of glucose transporters, cells were incubated with
2-NBDG (N13195; Molecular Probes) for 30 minutes, wa-
shed three times, and then stained with anti-Glut1-PE
(MAB1418; R&D Systems) for 20 minutes. Cells were then
washed and fixed with 4% paraformaldehyde.
Staining and incubations were performed at 37C. Un-
treated cells were used as controls. Fluorescent signals from
cells were acquired on BD FACS Canto II flow cytometer and
data were analyzed using Cyflogic software v. 1.2.1.
Immunofluorescence microscopy
Imaging of mitochondria and lipid droplets was performed
by washing preactivated cells after 48 hours and plating them
on poly-d-lysine (Sigma)-coated cover slips, and stained with
MitoTracker Deep Red FM (1:1000) and HCS LipidTOX
Green Neutral Lipid Stain (1:2000), respectively. After
staining, cells were washed once with PBS, followed by a 10-
minute incubation in PBS; this was then replaced with fresh
PBS. Fixed cells were also stained with Alexa 568-
conjugated anti-GAPDH antibody (D16H11; CST). Cover
slips were mounted with Duolink In Situ Mounting Medium
with DAPI (DUO82040; Sigma). Cells in five randomly se-
lected optical fields per replicate were visualized and images
were acquired using a Axio Observer Zeiss microscope with
objective LD ‘‘Plan-Neofluar’’ 20 · /0.4 Corr Ph2 M27, and
analyzed with ZEN Pro 2012 software.
Gel electrophoresis and western immunoblotting
Cells were lysed with RIPA buffer with 1 mM PMSF and
protease inhibitor cocktail. Twenty micrograms of protein
lysate was resolved by 10%–12% SDS-PAGE (sodium do-
decyl sulfate–polyacrylamide gel electrophoresis), trans-
ferred to PVDF membranes (Bio-Rad), blocked, and probed
with the primary antibodies: anti-ACL (phospho S455)
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(#4331; CST) and anti-Acetyl Coenzyme A Carboxylase
(phospho S79) (ab68191; Abcam, United Kingdom) fol-
lowed by appropriate horseradish peroxidase-conjugated
secondary antibodies (Cell Signaling Technology, United
Kingdom) and visualized using the ECL system (Perki-
nElmer Life Sciences).
Bioenergetics of T cells
CD4+ TEMs were stimulated with plate-bound anti-CD3
mAb or NIB1412 for 48 hours in complete media and then
resuspended in serum-free base media (102353-100; Sea-
horse Bioscience) with 2 mM l-glutamine –1 mM sodium
pyruvate –25 mM glucose. Subsequently, cells were seeded
in precoated poly-d-lysine (50mg/mL) XF 96-well micro-
plates (Seahorse Bioscience) at 3 · 105 cells per well, spun
down, and inoculated at 37C for 30 minutes. Bioenergetics
of CD4+ TEMs were determined using the XF Cell Mito Stress
Test Kit (103015-100; Seahorse Bioscience), XF Glycolysis
Stress Test Kit (102194-100; Seahorse Bioscience), and a
XFe96 Analyzer (Seahorse Bioscience). Briefly, following
the measurement of basal respiration, Oligomycin was injected
to inhibit ATP-synthase to measure the oxygen consumed for
ATP production during mitochondrial respiration-coupled
OXPHOS of ADP. The addition of the uncoupling agent 2,4-
DNP enabled measurement of the maximal respiratory capac-
ity of the cells. The final injection of rotenone and antimycin
A blocked the electron transport chain thus revealing non-
mitochondrial oxygen consumption. Glycolysis and the gly-
colytic reserve of cells were measured by the sequential
addition of glucose, Oligomycin, and 2-d-glucose. The ex-
tracellular acidification rate (ECAR) after glucose injection
is the basal rate of glycolysis and was higher in CD28SA-
stimulated cells than anti-CD3-stimulated cells. The addition
of Oligomycin inhibits mitochondrial ATP production and
shifts energy production predominantly to the glycolytic
pathway, revealing the maximum glycolytic capacity of the
cells. The glycolytic reserve is calculated from the difference
between the glycolytic capacity and glycolytic rate.
Acetyl-Coenzyme A measurement
Concentration of acetyl-CoA in whole-cell lysates from
preactivated CD4+ TEMs was measured by fluorescence assay
using a kit according to the manufacturer’s instructions (The
PicoProbe Acetyl CoA Assay Kit: ab87546; Abcam). Fluor-
escence was quantified using a Varioskan Flash Multimode
Plate Reader (Thermo Scientific, United Kingdom).
Citrate and alpha-ketoglutarate measurement
Concentration of citrate and alpha-ketoglutarate (a-KG)
in whole-cell lysates from preactivated CD4+ TEMs was
measured by fluorescence assay using a kit according to the
manufacturer’s instructions (The Citrate Assay Kit: ab83396,
a-KG Assay Kit: ab83431; Abcam). Relative fluorescence
units/intensity were quantified using a Varioskan Flash
Multimode Plate Reader (Thermo Scientific).
Statistical analysis
Unpaired, two-tailed Student’s t-test was used to analyze
data and results were presented as mean – standard deviation.
p < 0.05 was considered to be statistically significant.
Results
CD28SA-activated TEMs cells display
a hyperactive phenotype
T cell activation triggers metabolic programs that promote
biomass generation, which is evident by an increase in cell
size, termed blasting. We used a TGN1412-like CD28SA
mAb, termed NIB1412 to stimulate CD4+ TEMs and dem-
onstrate that the percentage of blasting T cells in the
CD28SA-stimulated condition is about 4-fold (59% compared
to 14% with anti-CD3) greater than in the CD3-activated
condition (Fig. 1A). We also confirmed the hyperactive phe-
notype of CD28SA-activated T cells as evidenced by their
enhanced proliferative response (Fig. 1B).
CD28SA stimulation maximizes OXPHOS potential
To assess the contribution of OXPHOS to meet the energy
requirements during hyperactivation of CD4+ TEMs upon
CD28SA stimulation, we used extracellular flux analysis to
measure oxygen consumption rates (OCR), basal respiration,
ATP production, maximal respiration and spare respiratory
capacity (SRC). CD28SA-stimulated T cells had higher basal
respiration and ATP production when compared with anti-
CD3-activated CD4+ TEMs (Fig. 2A). To determine whether
FIG. 1. CD28SA-activated CD4+ TEMs display a hyper-
active phenotype. (A) Size (FSC) and granularity (SSC)
were quantified by flow cytometry. FSC and SSC were
measured on purified human CD4+ TEMs stimulated with
anti-CD3 or CD28SA for 48 hours. Percentages – SD indi-
cate T cell blasts. The data are representative of four inde-
pendent experiments. (B) Human CD4+ TEMs were stimulated
with the indicated concentrations of plate-bound antibodies
(anti-CD3 or NIB1412) and proliferation was measured 3
days postactivation by 3H-labeled thymidine incorporation.
The vertical axis represents mean cpm–SD from triplicate
wells. The data are representative of four independent ex-
periments (**p< 0.01; unpaired, two-tailed Student’s t-test).
NIB1412–CD28SA. CD28SA, CD28 superagonist; cpm,
counts per minute; FSC, forward scatter; SD, standard de-
viation; SSC, side scatter; TEMs, effector memory T cells.
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CD28SA-stimulated T cells had more active mitochondrial
mass, we stained CD4+ TEMs with MitoTracker Deep Red and
found that CD28SA stimulation led to a higher quantity of
actively respiring mitochondria than when activated with
anti-CD3 mAbs (Fig. 2B, C). CD28SA-stimulated T cells
also produced more mitochondrial reactive oxygen species
(mitoROS) than anti-CD3-activated CD4+ TEMs (Fig. 2D),
which is reflective of enhanced mitochondrial electron
transport activity. Collectively, these results indicate that
CD28SA-activated cells maximize their OXPHOS potential,
which is supported by their greater active mitochondrial
mass. To test whether CD28SA-stimulated cells are reliant on
OXPHOS for their hyperproliferation, we cultured activated
CD4+ TEMs under hypoxic or normoxic conditions. While,
CD3-stimulated cells proliferated more in normoxic than in
hypoxic condition, CD28SA-stimulated cells proliferated in
both the conditions with higher rate of proliferation in hypoxic
condition (Fig. 2E). This suggests that CD28SA-activated T
cells have a flexible metabolic program that reduces the reli-
ance on OXPHOS for proliferation.
FIG. 2. CD28SA stimulation maximizes OXPHOS potential. (A) OCR (pMoles/min) of preactivated human CD4+ TEMs
were measured using the seahorse XF96 extracellular flux analyzer in real time, under basal conditions and in response to
sequential addition of Oligomycin (1 mM), 2,4-DNP (160mM), and antimycin A and rotenone (1 mM). Mean OCR values
representing basal respiration and ATP production are presented as bar charts. The bars represent the mean –SD. The data
are representative of three independent experiments (**p< 0.01; unpaired, two-tailed Student’s t-test). (B) IF images of
mitochondria. IF images show anti-CD3- and CD28SA-stimulated human CD4+ TEMs stained with MitoTracker (red) and
Hoechst (blue); far right quadrant represents merged image of the two stains; scale bars represent 10 mm. (C) Mitochondria
were stained with MitoTracker Deep Red or (D) MitoSOX Red Mitochondrial Superoxide Indicator, and the staining
intensities were quantified by flow cytometry. Data represent the mean – SD percentage of cells staining positive for
mitochondria, oitoROS, with the mean percentage of mitoROS present in activated CD4+ TEMs. Mean – SD were obtained
from three independent experiments (**p < 0.01; unpaired, two-tailed Student’s t-test). (E) Human CD4+ TEMs were
stimulated with the indicated concentrations of plate-bound antibodies (anti-CD3 or NIB1412) and incubated in normoxic
(20% O2) or hypoxic (5% O2) conditions. Proliferation was measured 3 days postactivation by
3H-labeled thymidine
incorporation. The vertical axis represents mean cpm – SD from triplicate wells. The data are representative of three
independent experiments (**p < 0.01; unpaired two-tailed t-test). NIB1412–CD28SA. IF, immunofluorescent; mitoROS,
mitochondrial reactive oxygen species; OCR, oxygen consumption rates; OXPHOS, oxidative phosphorylation.
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CD28SA stimulation maximizes glucose utilization
To assess glucose handling during CD28SA stimulation,
we measured ECAR, a marker of glycolysis, and found that
CD28SA-stimulated CD4+ TEMs displayed significantly
higher glycolysis and lacked glycolytic reserve compared
with anti-CD3-stimulated cells (Fig. 3A). This result indi-
cates that CD28SA-activated cells adopt a metabolic pro-
gram that maximizes basal glycolytic rate. We tested whether
the high glycolytic rate was associated with altered glycolytic
machinery in CD4+ TEMs. The enzyme GAPDH is a critical
component of the glycolytic pathway that generates pyruvate
FIG. 3. CD28SA stimulation maximizes glucose utilization. (A) ECAR (mpH/min) of preactivated human CD4+ TEMs
were measured using the seahorse XF96 extracellular flux analyzer in real time, under basal conditions, and in response to
sequential addition of glucose (10 mM), Oligomycin (1 mM), and 2-DG (100 mM). Mean ECAR values representing gly-
colysis and glycolytic reserve are presented as bar charts. The bars represent the mean – SD. The data are representative of
three independent experiments (**p < 0.01; unpaired two-tailed t-test). (B) Immunofluorescence images show anti-CD3- and
CD28SA-stimulated human CD4+ TEMs at 48 hours postactivation stained with anti-GAPDH (green) and DAPI (blue); scale
bars represent 10 mm. Far right quadrant represents merged image of the two stains. (C) Human CD4+ TEMs were stimulated
with anti-CD3 or CD28SA for 48 hours. Cells were then incubated with 2-NBDG for 30 mins and the amount of 2NBDG
uptake (i) was measured by flow cytometry, with the mean percent of 2-NBDG-positive CD4+ TEMs presented in a bar
graph. The bars represent the mean –SD from three different experiments (**p < 0.01; unpaired two-tailed t-test). Cells were
also stained for Glut1 expression (ii). The data are representative of three independent experiments. (D) Basal ECAR and
OCR of preactivated human CD4+ TEMs were measured using the seahorse XF96 extracellular flux analyzer in real time,
with the (i) ECAR/OCR ratio presented as bar charts. The bars represent the mean – SD. The data are representative of three
independent experiments (*p < 0.05, **p < 0.01; two-tailed unpaired t-test). (ii) Cell viability of anti-CD3- and CD28SA-
stimulated human CD4+ TEMs cultured for 24 hours in the presence or absence of glucose. Percentage of viable cells was
determined by using Trypan Blue. The data are representative of three independent experiments (**p < 0.01; unpaired two-
tailed t-test). NIB1412–CD28SA. 2-DG, 2-deoxy-d-glucose; ECAR, extracellular acidification rate.
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FIG. 4. CD28SA activation induces de novo lipogenesis. (A) OCR (pMoles/min) of preactivated human CD4+ TEMs were
measured using the seahorse XF96 extracellular flux analyzer in real time, under basal conditions, and in response to
sequential addition of Oligomycin (1 mM), 2,4-DNP (160mM) and antimycin A and rotenone (1 mM). Etomoxir (200mM) or
medium was injected after 2,4-DNP injection. The SRC (quantitative difference between maximal uncontrolled OCR –
etomoxir treatment and initial basal OCR) was calculated and presented as the percentage contribution of FAO to SRC in
bar charts. The bars represent mean – SD. The data are representative of three independent experiments (**p < 0.01;
unpaired two-tailed t-test). (B) Immunofluorescence images show (i) anti-CD3- and CD28SA-stimulated CD4+ TEMs at 48
hours postactivation stained with LipidTOX (green) and DAPI (blue); scale bars represent 10 mm. Far bottom quadrant
represents merged image of the two stains. (ii) LipidTOX staining was quantified by flow cytometry. Data represent the
mean percent of cells – SD (n = 3) staining positive for neutral lipids. (C-i) Relative levels of acetyl-CoA in anti-CD3- and
NIB1412-stimulated TEMs at 48 hours postactivation; mean – SD of triplicates (**p< 0.01). (ii) Expression of p-ACC
(250 kDa) and p-ACL (125 kDa) by western blot. (iii) Expression of p-ACC with IL-2 condition, in anti-CD3- and
NIB1412-stimulated TEMs at 48 hours postactivation, and (iv) Expression of p-ACC and p-ACL in human malignant
melanoma cells (A375), human ovarian tumor cells (A2780), hepatocellular cells (HepG2), human cervical cancer cells
(HeLa), human monocytic leukemia cells (THP-1), human T cell lymphoblast-like cells ( Jurkat), and unstimulated TEMs
was determined by western blot. Actin (45 kDa) was used as a loading control. (D) Alpha-ketoglutarate-to-citrate ratio in
anti-CD3- and CD28SA-stimulated human CD4+ TEMs at 48 hours postactivation, presented as bar charts. The bars
represent the mean –SD of triplicate measurements (*p < 0.05; unpaired two-tailed Student’s t-test). NIB1412–CD28SA.
ACC, acetyl-CoA carboxylase; ACL, ATP-citrate lyase; FAO, fatty acid oxidation; SRC, spare respiratory capacity.
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from glucose (Supplementary Fig. S1) with cytoplasmic
distribution of GAPDH being indicative of glycolytic activ-
ity. We examined the cellular distribution of GAPDH by
immunofluorescence and observed that the distribution of
GAPDH staining was coincident with nuclear contours in
anti-CD3-stimulated CD4+ TEMs (Fig. 3B). In contrast,
CD28SA-stimulated CD4+ TEMs had more dispersed cyto-
solic distribution of GAPDH (Fig. 3B).
Increased glycolytic rates need to be fuelled by a com-
mensurate increase in the uptake of glucose, which is pre-
dominantly mediated by the glucose transporter, GLUT1 in T
cells. The uptake of the fluorescent glucose analog 2-NBDG
(Fig. 3C-i) and cell surface expression of GLUT1 (Fig. 3C-ii)
were both higher in CD28SA-stimulated CD4+ TEMs than in
CD3-stimulated cells. The ratio of the basal ECAR to OCR
indicates the cellular preference for glycolysis versus OX-
PHOS metabolic programs.(12) Figure 3D-i shows the
ECAR/OCR ratio of CD28SA- and anti-CD3-stimulated T
cells cultured (in base media with glutamine only) in the
absence of glucose (-Glu) or in the presence of glucose
(+Glu). In the -Glu condition the ECAR/OCR ratio was
significantly lower in CD28SA-stimulated cells than anti-
CD3-stimulated cells. In the +Glu condition CD28SA-
stimulated cells had a significantly higher ECAR/OCR ratio
than anti-CD3-stimulated cells. These plots demonstrate that
in the presence of glucose, CD28SA-stimulated cells pref-
erentially drive glycolysis, whereas anti-CD3-stimulated
cells also drive OXPHOS. Collectively these results show
that CD28SA stimulation drives an adaptable metabolic
program that maximizes glucose utilization to drive both
OXPHOS and glycolysis depending on glucose availability.
This is further demonstrated by cell viability in glucose-
deficient conditions wherein viability of CD28SA-stimulated
cells was unaffected after 24 hours while more than 50% of
the CD3-stimulated cells died (Fig. 3D-ii).
CD28SA-activated T cells are metabolically
programmed to favor lipogenesis
To determine whether mitochondrial fatty acid oxidation
(FAO) contributes to OXPHOS, we measured changes in
SRC in the presence of the Carnitine palmitoyl transferase
(CPT1a) inhibitor, etomoxir (CPT1a is involved in transfer of
fatty acids from cytosol to the mitochondria). In both +Glu
and -Glu conditions, around 80% of FAO contributed to the
SRC of CD3-stimulated CD4+ TEMs. In contrast, only about
30% of FAO contributed to the SRC of CD28SA-stimulated
cells in -Glu while there was no contribution of FAO to the
SRC in the +Glu conditions (Fig. 4A). The low rate of FAO in
CD28SA-activated CD4+ TEMs suggested the possibility that
these cells are potentially increasing their lipid reserve. Li-
pidTox staining revealed that CD28SA stimulation induces
a significantly greater accumulation of neutral lipids in CD4+
TEMs than when activated with anti-CD3 mAbs (Fig. 4B-i).
This was confirmed and quantified by flow cytometry
(Fig. 4B-ii). We next measured the acetyl-CoA content and
demonstrate that total acetyl-CoA levels were significantly
higher in CD28SA-stimulated CD4+ TEMs than in CD3-
stimulated cells (Fig. 4C-i). The increased lipogenesis in
CD28SA-stimulated cells is reflected by the hyperactivity of
the lipogenic enzymes, ACL and ACC, as determined by
their phosphorylation status (Fig. 4C-ii). Hyperactivation of
ACL and ACC has been reported in tumor cells and we con-
firmed this in several types of tumor cell lines (Fig. 4C-iv).
To rule out the influence of the CD28SA-secreted IL-2 on
the de novo lipogenesis, we also activated CD4+ TEMs with
anti-CD3 in combination with IL-2 (aCD3+IL-2), and with
anti-CD3 in combination with conventional anti-CD28 (aC-
D3+aCD28). As can be seen in the results, CD28SA-stimulated
cells had significantly greater ACC phosphorylation than any
of the other conditions (Fig. 4C-iii). This indicates that the
enhanced lipogenic program in CD28SA-activated CD4+ TEMs
is not secondary to IL-2 effects. We observed that CD3-
stimulated CD4+ TEMs possessed a high relative a-KG/citrate
ratio of 2.2– 0.3, suggesting ongoing reductive glutamine
metabolism (Fig. 4D). In contrast, CD28SA-stimulated cells
had a low relative a-KG/citrate ratio of 0.6– 0.1 indicative of
an absence of reductive glutamine carboxylation (Fig. 4D).
Collectively, these results show that CD28SA-stimulated
cells have a dominant program of endogenous biosynthesis
of fatty acids, which was not accompanied by preferential
reductive glutamine metabolism. Our results show that
CD28SA stimulation induces a tumor cell-like metabolic
phenotype, where increased glycolytic flux correlates with
elevated de novo lipogenesis and reduced FAO.
Discussion
The metabolic programming of T cells is an area of intense
investigation with implications for therapeutic intervention
in many disease areas.(13–16) We and others have previously
shown that CD28SA activation results in a hyperactive T cell
phenotype.(4,17) Activated immune cells prefer glycolysis
over OXPHOS as it is around two orders of magnitude faster
for biomass accumulation and proliferation.(18) Nevertheless,
OXPHOS is necessary for cell-surface expression of the IL-2
receptor and thus vital for lymphocyte proliferation.(19)
In the current study, we find that CD28SA-stimulated TEMs
cells had higher levels of ATP production, basal respiration,
and actively respiring mitochondria compared with anti-
CD3-activated TEMs. The high oxygen consumption and ATP
production is indicative of enhanced rates of OXPHOS,
which occurs primarily in the mitochondria.(20) Studies have
shown that an increase in mitochondrial mass results in an
increase in overall mitochondrial function, with a boost in
residual OXPHOS capacity and an increase in overall ATP-
generating capacity.(21,22) Furthermore, our observation of
increased mitoROS in CD28SA-stimulated TEMs cells is re-
flective of enhanced mitochondrial electron transport activi-
ty.(23) MitoROS production is regulated by mitochondrial
membrane potential (Dcm), metabolic state of mitochondria,
and oxygen concentration.(24) Mitochondrial mass and Dcm
are known to be significantly increased in cells during cell
cycle, particularly when they are in S phase(25) and we have
shown in a previous study(4) that a high proportion of
CD28SA-stimulated cells are in S-phase at 48 hours post-
activation and onward. Thus, the elevated mitochondrial
mass and mitoROS might be due to the rapid cell prolifera-
tion induced by CD28SA activation. We also observed that
CD28SA-stimulated cells proliferated in both normoxic and
hypoxic conditions with higher rate of proliferation in the
latter. These observations indicate that CD28SA-activated
T cells have a flexible metabolic program that reduces the
reliance on OXPHOS for proliferation.
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We observed that CD28SA stimulation maximizes glucose
utilization with higher glycolysis and a deficient glycolytic
reserve. The T cell machinery has to be configured to support
the higher glycolytic rate. Studies have shown that GAPDH
shuttles between nuclear and cytoplasmic compartments,
with cytoplasmic GAPDH being active in glycolysis,(26)
while nuclear GAPDH is thought to be involved in the ini-
tiation of apoptotic cascades(27) and promoting gene tran-
scription.(28,29) We observed a predominant cytosolic
distribution of GAPDH in CD28SA-stimulated TEMs as well
as increased cell surface GLUT1 expression, supportive of
enhanced glucose uptake and utilization.(30) In keeping with a
role for CD28 in this process, CD28 costimulation (in addi-
tion to TCR activation), acting through the PI3K/Akt path-
way is an important component in increasing glycolytic flux
essential for T cell proliferation.(31) Interestingly, the adapt-
able metabolic program induced by CD28SA in T cells
(which is accompanied by supportive cellular changes) is
reminiscent of the metabolic and cellular changes seen in
tumor cells. For example, a variety of tumor cells show up-
regulation of GAPDH together with its accumulation in the
cytoplasm,(29) exhibit elevated levels of glucose uptake and
glucose transporters, and(32) can survive in vitro in the
complete absence of glucose if supplied with glutamine.(33)
Mitochondrial FAO is a source of acetyl CoA that is used
in the TCA cycle for energy generation through OX-
PHOS.(34) CPT1a is a metabolic enzyme that controls the
rate-limiting step in mitochondrial FAO.(35) IL-2-secreting
CD8+ effector memory T cells store exogenous long-chain
fatty acids in lipid droplets, which are then mobilized for
mitochondrial FAO.(8) In contrast, CD8+ memory T cells
were shown to use extracellular glucose to synthesize fatty
acids for neutral lipid stores,(8) which then undergo lipolysis
to supply fatty acids for FAO as well as for incorporation into
cellular membrane structures.
The lipid reserve of T cells is determined by the balance
between lipogenesis and rate of FAO.(8) De novo fatty acid
biosynthesis is not only required to synthesize new mem-
branes for cell proliferation but also to facilitate the formation
of lipid rafts for increased signaling of cell surface recep-
tors.(36) Accumulated neutral lipid stores are then mobilized
to provide free fatty acids to promote production of signaling
lipids, for incorporation into cellular membranes or for the
production of ATP through b-oxidation.(37) Although the
dynamics of fatty acid utilization for FAO has not been
shown in CD4+ TEMs, in this report we propose that CD28SA
stimulation enables CD4+ TEMs to promote endogenous
biosynthesis of fatty acids similar to cancer cells, which are
known to undergo a metabolic shift toward pronounced in-
crease in de novo lipid biosynthesis.(38)
Lipogenesis requires the availability of acetyl-CoA, which
is an essential substrate for the endogenous biosynthesis of
fatty acids. Increased glycolysis can shunt glucose-derived
pyruvate into the mitochondria to be decarboxylated to
acetyl-CoA, and then condensed with oxaloacetate to form
citrate.(39) Citrate is then exported from the mitochondria
through the malate citrate shuttle system and used as a sub-
strate for ACL.(40) ACL is a key cytosolic enzyme that ca-
talyses the generation of acetyl-coenzyme A (CoA) from
mitochondria-derived citrate. Acetyl-CoA is then carboxyl-
ated to malonyl-CoA by ACC, which subsequently results in
fatty acid synthesis. The activity of ACL and ACC are in-
creased by serine phosphorylation.(41,42) We report that total
acetyl-CoA levels were significantly higher along with in-
creased activity of ACL and ACC in CD28SA-stimulated
TEMs than in CD3-stimulated cells. We also show that IL-2
derived from CD28SA-stimulated T cells(43) did not con-
tribute to the enhanced lipogenic program observed in
CD28SA-activated TEMs. The rapid proliferation of several
types of cancer cells is dependent on the enhanced activity of
ACL, with elevated acetyl-coA levels and increased activity
of lipid-metabolizing enzymes being increasingly recognized
as a feature of cancer cells.(44,45) This metabolic program is
now observed in CD28SA-stimulated TEMs.
ACL and ACC represent committed steps in channeling
glucose-derived metabolites toward a lipid biosynthetic fate,
which is regulated by PI3K/Akt signaling.(46) This is con-
sistent with the activation of the PI3K pathway by engage-
ment of CD28 by the superagonistic mAb.(47) The acetyl CoA
that feeds lipogenesis is primarily derived from citrate.(48)
The citrate can be produced from glucose-derived pyruvate
that enters the TCA cycle. A recent study has shown that in
cancer cells, glutamine can enter the TCA cycle and also
become a source of citrate for de novo lipogenesis through
reductive carboxylation of glutamine-derived a-KG(49)
(Supplementary Fig. S1). An elevated a-KG/citrate ratio was
shown to be the principal driving force for reductive glutamine
metabolism(49) and we observed a low relative a-KG/citrate
ratio in CD28SA-stimulated TEMs cells indicative of an ab-
sence of reductive carboxylation, unlike anti-CD3-stimulated
TEMs. Elevated glycolytic flux is associated with de novo li-
pogenesis and reduced FAO. CD28SA-stimulated TEMs ex-
hibited increased glycolytic flux similar to cancer cells where
intermediate metabolites are channeled toward acetyl-CoA
generation for use in de novo fatty acid biosynthesis.(36)
The tumor microenvironment (TME) is rendered hostile to
the survival and function of tumor infiltrating effector T cells
by the remodeling effects of tumor cells. Tumor cells achieve
this through a number of mechanisms, including establishing
a hypoxic milieu, depleting extracellular glucose, secreting
metabolites that impair immunity and by enhancing expres-
sion of ligands for immune checkpoints such as PD-1 to
maintain T cell exhaustion.(50) Current immunotherapies
based on checkpoint inhibitors target limited pathway/s in-
volved in immune evasion. A comprehensive immunothera-
peutic strategy should be aimed at increasing T cell fitness
through countering multiple aspects of tumor cell remodeling
of TME. Our results suggest that T cells that have been
metabolically reprogrammed through the CD28SA pathway
will have superior fitness in the TME owing to their increased
tolerance to hypoxia and a flexible metabolic program, much
alike tumor cells. Furthermore, we have also previously
shown that CD28SA-activated T cells can escape inhibition
through the PD-1 pathway.(4) Our findings indicate that im-
munotherapies that induce T cell metabolic reprogramming
similar to CD28SA-activated T cells will enhance the efficacy
of tumor-infiltrating T cells. For example, it can be envisaged
that chimeric antigen receptor T cells that are modified to
exploit the metabolic reprogramming of the CD28SA pathway
will have superior efficacy and persistence in the TME.
In summary, we have shown that CD28SA activation in-
duces a tumor cell-like T cell metabolic program that is
geared toward maximal glucose utilization, endogenous lipid
synthesis, and less dependence on OXPHOS. Tumor cells
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frequently exhibit similar alterations in metabolic activity to
support the increased production of metabolic intermediates
for the synthesis of proteins, nucleic acids, and lipids. We
have also defined ACL and ACC as the likely molecular
components that support operation of this metabolic pro-
gram. Our study provides insights into the remarkable ca-
pacity of T cells to adopt a variety of distinct metabolic
programming depending on the pathways that are engaged.
Our results may also have implications and utility in drug
development, as dysregulated metabolic patterns in immune
cells treated with therapeutic mAbs could serve as novel
biomarkers of hazard identification. For example, aberrant
nutrient uptake and utilization, together with increased de
novo lipid biosynthesis could be indicative of excessive im-
munostimulatory potential of the therapeutic mAb. Meta-
bolic studies that compare a number of immunostimulatory
therapeutic mAbs are required to examine this further.
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